Tobacco-Derived Plant Molecule Solanesol Matches Metformin at 40-Fold Lower Dose in Diabetic Mice

A long-overlooked plant molecule best known as a building block for coenzyme Q10 supplements has emerged as a strikingly potent antidiabetic agent in its own right. In a comprehensive study published in the Journal of Advanced Research, researchers report that solanesol, a forty-five-carbon terpenoid abundant in tobacco leaves, potatoes, and tomatoes, reversed insulin resistance, fatty liver disease, pancreatic inflammation, and elevated uric acid in mice with type 2 diabetes — all at a dose forty times lower than the metformin regimen it was compared against. The work, led by Wenji Zhang and Wenjuan Zhang together with colleagues, combined classical metabolic testing with an unusually deep multi-omics interrogation spanning the transcriptome, proteome, gut microbiome, and fecal metabolome.

The experimental setting was the Leprdb/db mouse, a genetically obese animal that progressively develops the hallmarks of human type 2 diabetes: hyperglycemia, hyperinsulinemia, dyslipidemia, and systemic insulin resistance. Thirty diabetic mice were divided into a model group, a metformin group receiving 200 milligrams per kilogram per day, and three solanesol groups receiving 1, 5, or 15 milligrams per kilogram per day by oral gavage for 45 days. Six healthy C57BL/6J mice served as controls. Over the intervention window the team ran serial glucose tolerance and insulin tolerance tests, tracked fasting glucose weekly, and quantified a panel of serum and hepatic biochemical markers before dissecting liver, kidney, adipose depots, and fecal samples for molecular analysis.

The metabolic results were remarkable. By week six, medium-dose solanesol had reduced the insulin tolerance test area under the curve to 60.9 percent of untreated diabetic levels, marginally outperforming metformin’s 66.3 percent. Glycated serum protein, a marker of longer-term glucose exposure, fell to 74.8 to 78.4 percent of model values across all solanesol doses, mirroring metformin. Crucially, the homeostatic model assessment of insulin resistance dropped by roughly 84 percent in solanesol-treated animals versus 81.8 percent with metformin, while circulating insulin remained unchanged — evidence that the compound works by sensitizing tissues to insulin rather than by goading beta cells into secreting more of it. That non-secretagogue profile distinguishes solanesol from sulfonylureas and their well-known hypoglycemia risk.

Lipid outcomes were arguably even more impressive. High-dose solanesol drove low-density lipoprotein cholesterol down to 34.6 percent of diabetic levels, compared with only 62.3 percent under metformin, and cut triglycerides to roughly half of model values. White adipose tissue mass shrank significantly, brown adipose tissue expansion was curtailed, and the animals’ leptin-driven hyperphagia and polydipsia partially normalized. Histologically, the enlarged, pale, fat-infiltrated livers of diabetic mice regained near-normal architecture under medium and high-dose solanesol, with PAS staining revealing a threefold restoration of hepatic glycogen storage — a benefit metformin did not achieve. Masson’s trichrome staining confirmed the absence of fibrosis in all groups, pointing to a hepatoprotective rather than toxic profile even at the highest dose administered.

The pancreatic findings add a distinctive anti-inflammatory dimension. Solanesol suppressed interleukin-1 beta, the pivotal inflammasome-driven cytokine in islet inflammation, by 37 to 42 percent across doses, exceeding metformin’s 30 percent reduction, while leaving TNF-alpha, IL-6, and IL-10 untouched. This pinpoint suppression occurred alongside preserved C-peptide and insulin secretion, suggesting the compound shields beta cells from inflammatory stress without disturbing their secretory machinery. In the kidney, solanesol delivered an unexpected bonus: serum uric acid fell to 65 to 70 percent of diabetic levels, an effect achieved independently of hepatic xanthine oxidase and therefore likely involving reprogramming of renal urate transporters. Because 17 to 22 percent of diabetic patients suffer comorbid gout, and metformin’s own uric acid profile was neutral to slightly adverse, this anti-hyperuricemic activity could prove clinically significant.

To uncover mechanism, the team sequenced the hepatic transcriptome, generating 82.63 gigabases of high-quality data, and profiled the liver proteome by 4D label-free quantification on a timsTOF Pro2 mass spectrometer. Differential expression analysis revealed thousands of genes dysregulated in diabetic livers, with a conspicuous cluster of 31 oxidative phosphorylation-related genes overexpressed in disease. Network analysis identified hub nodes concentrated in respiratory chain complexes I, III, IV, and V — including Ndufa5, Cox6b1, Atp5h, and Uqcrb — and solanesol treatment normalized this pathological signature. Enzyme assays told the deeper story: although respiratory chain gene expression was elevated in diabetic mice, actual complex activity was reduced, an apparently futile compensatory response that drives ATP depletion and reactive oxygen species generation. Solanesol reversed the functional impairment, restoring electron transport across complexes I through V, a coordinated rebalancing that contrasts with metformin’s singular inhibition of complex I.

The proteomic and qPCR data converged on a second mechanistic axis: lipid metabolic reprogramming. Six core regulators — Apoa4, Acaca, Acly, Fasn, Abca1, and Fabp5 — showed concordant changes across transcriptomic and protein platforms. Solanesol suppressed the Acly-Acaca-Fasn cascade that drives de novo lipogenesis, blocking the conversion of citrate to acetyl-CoA and onward to fatty acids, while simultaneously upregulating Abca1 to promote cholesterol efflux and Fabp5 to channel fatty acids into mitochondrial beta-oxidation. Reduced free fatty acid flux then relieved the abnormal PPAR-delta elevation seen in diabetic livers, tempering inflammation. The authors link Abca1 activation to JAK2-STAT3 signaling in macrophages that restrains NF-kappa-B-driven cytokine release, a dual metabolic-immune effect observed in islets and skeletal muscle as well as liver.

Perhaps the most systems-level findings came from the gut. Sequencing of the V3-V4 region of the bacterial 16S rRNA gene from 1.48 million high-quality sequences showed that solanesol restructured the diabetic microbiome, enriching beneficial taxa such as Alistipes and Anaerotruncus, known short-chain fatty acid producers, along with Odoribacteraceae and Parasutterella, implicated in bile acid metabolism and PPAR signaling. Fecal metabolomics by LC-MS/MS identified 97 disease-elevated metabolites that solanesol normalized, mapping onto bile acid biosynthesis, taurine metabolism, and steroid hormone pathways, while restoring 43 depleted metabolites tied to alpha-linolenic acid metabolism and oxidative phosphorylation. Quantitative fatty acid profiling revealed a chain-length-dependent pattern: fecal short-chain fatty acids fell further under treatment, consistent with enhanced intestinal absorption of these beneficial molecules, medium-chain fatty acids normalized, and long-chain fatty acids rebounded toward healthy levels, including rises in palmitoleate, gamma-linolenate, and eicosatrienoate — lipids connected to gut-liver and gut-brain signaling.

Those neuroactive lipid shifts resonate with prior work showing solanesol’s neuroprotection in models of Huntington’s disease, autism spectrum disorder, cerebral hemorrhage, and bipolar disorder, effects attributed to mitochondrial restoration and SIRT-1 activation. The new data also reposition the molecule relative to coenzyme Q10 itself. Solanesol significantly elevated ubiquinone-1, a CoQ10 precursor, yet conventional CoQ10 supplementation suffers from oral bioavailability below 5 percent and has failed to improve glycemic control in meta-analyses of diabetic patients. Solanesol appears to bypass those pharmacokinetic limitations, prompting the authors to propose a precursor-to-therapeutic repositioning strategy in which the intermediate outperforms the end product it was once merely used to synthesize.

The authors are candid about limitations: the six-mice-per-group design and the roughly seven-week intervention cannot capture subtle trends or long-term complication prevention, and they call for extended studies of six months or more, diverse disease models, and eventual clinical evaluation. Still, the breadth of benefit — hepatic steatosis reduced by about 59 percent, pancreatic IL-1beta by about 42 percent, serum uric acid by about 45 percent, plus microbiome and metabolome remodeling — achieved at 5 milligrams per kilogram per day, marks solanesol as a rare multi-target natural modulator of what the team calls the metabolic quartet: dysglycemia, dyslipidemia, hyperuricemia, and multi-organ inflammation. If those effects translate beyond rodents, a molecule extracted from tobacco waste streams could become an unexpected weapon against one of the world’s fastest-growing pandemics.

Subject of Research: Multi-organ protective mechanisms of the plant compound solanesol against insulin resistance in type 2 diabetic mice, revealed through integrated multi-omics analysis.

Article Title: Integrated multi-omics unravels solanesol’s multi-organ protection mechanisms against insulin resistance in type 2 diabetic mice

Article References: Zhang, W., Cheng, W., Fu, J., Zeng, R., Wang, Z., Zhou, J., Chen, Y., & Zhang, W. (2026). Integrated multi-omics unravels solanesol’s multi-organ protection mechanisms against insulin resistance in type 2 diabetic mice. Journal of Advanced Research, 87, 1011-1026. https://doi.org/10.1016/j.jare.2025.12.025

Image Credits: AI Generated

DOI: 10.1016/j.jare.2025.12.025

Keywords: solanesol, type 2 diabetes, insulin resistance, metformin, multi-omics, mitochondria, oxidative phosphorylation, gut microbiome, fatty liver, hyperuricemia, db/db mice, natural products